Shareholders Equity: The sum of preferred and common equity items.
Nektar Therapeutics (NKTR) had Shareholders Equity of $89.83M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$55.23M |
|
$-164.08M |
|
-- |
|
$55.23M |
|
$195.33M |
|
$-140.10M |
|
$-15.38M |
|
$-155.49M |
|
$-155.49M |
|
$-155.35M |
|
$-164.08M |
|
$-164.08M |
|
$-155.35M |
|
$-140.10M |
|
$-139.08M |
|
16.87M |
|
16.87M |
|
$-9.73 |
|
$-9.73 |
|
| Balance Sheet Financials | |
$266.27M |
|
$2.06M |
|
$14.14M |
|
$280.41M |
|
$53.54M |
|
-- |
|
$137.04M |
|
$190.57M |
|
$89.83M |
|
$89.83M |
|
|
Shareholders Equity |
$89.83M |
20.38M |
|
| Cash Flow Statement Financials | |
$-208.51M |
|
$-1.20M |
|
$180.57M |
|
$44.25M |
|
$15.12M |
|
$-29.14M |
|
$12.65M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.97 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-253.66% |
|
-253.66% |
|
-251.80% |
|
-281.52% |
|
-297.07% |
|
$-208.68M |
|
-- |
|
-- |
|
-- |
|
0.20 |
|
-- |
|
-- |
|
-- |
|
-182.65% |
|
-182.65% |
|
-58.51% |
|
-182.65% |
|
$4.41 |
|
$-12.37 |
|
$-12.36 |
|